Barrett's Esophagus

Detection tools more accurately identified patients at risk for neoplastic Barrett’s esophagus compared with frequency and duration of GERD, according to results published in Gastroenterology.

The FDA has given breakthrough device designation to the EsoGuard Esophageal DNA Test designed to help identity patients at higher risk for dysplasia due to chronic GERD, according to a press release from Lucid Diagnostics.

Researchers developed a deep-learning, computer aided system that detected neoplasia in patients with Barrett’s esophagus at a better rate than nonspecialized endoscopists, according to study results.

SAN ANTONIO — Biopsies using a wide-area transepithelial sampling brush helped diagnose intestinal metaplasia in patients with no prior history, according to study results presented at the American College of Gastroenterology Annual Meeting.

SAN ANTONIO — Treatment with endoscopic submucosal dissection helped lower recurrence rates and reduce the need for repeat treatment in patients with Barrett’s esophagus-associated early neoplasia, according to study results presented at the American College of Gastroenterology Annual Meeting.

ASGE has released updated guidelines for the screening and surveillance of Barrett’s esophagus.

Recently published studies have demonstrated new developments in Barrett’s esophagus and achalasia.

Patients with Barrett’s Esophagus with indefinite for dysplasia are at similar risk for malignant progression and should be screened like patients with low-grade dysplasia, according to results of a meta-analysis published in Gastrointestinal Endoscopy. “Currently, there are no reliable estimates for progression risk to [high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC)] in patients with [Barrett’s esophagus with indefinite for dysplasia (BE-IND)],” Prasad G. Iyer, MD, MSc, from the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota, and colleagues wrote. “Hence, management strategies for BE-IND are unclear and endoscopy is not routinely recommended.”